Progress in gene therapy for prostate cancer.
Progress in gene therapy for prostate cancer.
复制标题
DOI：
10.3389/fonc.2012.00172
复制
发表时间：
2012
影响因子：
4.7
通讯作者：
Morris JC
中科院分区：
文献类型：
--
作者：
Ahmed KA;Davis BJ;Wilson TM;Wiseman GA;Federspiel MJ;Morris JC
基因疗法有希望纠正各种疾病的过程。前列腺癌是美国男性癌症死亡的第二大原因。已经报道了许多涉及用于治疗前列腺癌的基因疗法的临床试验。用有效水平的治疗基因有效地抑制肿瘤的能力已被确定为有效癌症基因治疗的基本障碍。在我们的研究机构中，前列腺癌患者采用基因治疗的方法试图解决这一缺陷。钠碘同向转运体（NIS）负责甲状腺转运和浓缩碘的能力。NIS基因的特性表明它可能是一种理想的肿瘤治疗基因。马约诊所研究人员发表的结果表明，使用NIS基因和前列腺基因治疗取得了几项重要的成功。研究已经证明，使用腺病毒载体在体外和体内将人NIS基因转移到前列腺癌中导致放射性碘的有效摄取和显著的肿瘤生长延迟以及生存期的延长。临床前的成功最终导致了对晚期前列腺疾病患者的I期试验的开放，目前正在积累患者。进一步的研究将揭示NIS基因治疗在前列腺以及其他恶性肿瘤治疗中的临床前景。
Gene therapy has held promise to correct various disease processes. Prostate cancer represents the second leading cause of cancer death in American men. A number of clinical trials involving gene therapy for the treatment of prostate cancer have been reported. The ability to efficiently transduce tumors with effective levels of therapeutic genes has been identified as a fundamental barrier to effective cancer gene therapy. The approach utilizing gene therapy in prostate cancer patients at our institution attempts to address this deficiency. The sodium-iodide symporter (NIS) is responsible for the ability of the thyroid gland to transport and concentrate iodide. The characteristics of the NIS gene suggest that it could represent an ideal therapeutic gene for cancer therapy. Published results from Mayo Clinic researchers have indicated several important successes with the use of the NIS gene and prostate gene therapy. Studies have demonstrated that transfer of the human NIS gene into prostate cancer using adenovirus vectors in vitro and in vivo results in efficient uptake of radioactive iodine and significant tumor growth delay with prolongation of survival. Preclinical successes have culminated in the opening of a phase I trial for patients with advanced prostate disease which is currently accruing patients. Further study will reveal the clinical promise of NIS gene therapy in the treatment of prostate as well as other malignancies.